Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has been informed of the investigational nature of this study and has given written informed consent in accordance with institutional, local, and national guidelines.~* Able to return for Day 8 follow up.~* Male or female 18 years of age or greater.~* Onset of AF/AFL within the 7 calendar days preceding randomization, based on symptoms.~* AF/AFL documented by ECG during the screening period.~* Adherence to local clinical standards or the ACC/AHA or ESC practice guidelines for AF/AFL regarding thromboembolic event prevention and treatment.~Exclusion Criteria:~* Previous exposure to vanoxerine HCl.~* Women of childbearing potential (neither surgically sterilized nor post-menopausal defined as cessation of menses for over one year)~* Systolic blood pressure \<110 mmHg (unless documented to be usual value).~* Average heart rate \<60 bpm documented by screening ECG.~* Average QTc \>440 msec documented by screening ECG.~* QRS interval \>140 msec documented by screening ECG.~* Paced atrial rhythm on screening ECG.~* History of receiving another Class I or Class III antiarrhythmic drug within 3 days prior to randomization. Excluded Class I antiarrhythmic drugs include quinidine, procainamide, disopyramide, lignocaine, mexilitine, flecainide, and propafenone. Excluded Class III drugs include dofetilide, sotalol, dronedarone, and ranolazine.~* History of amiodarone (oral or IV) within the 90 days prior to randomization.~* Native or prosthetic aortic or mitral stenosis with aortic valve area ≤1.0 cm2 or mitral valve area of \<1.5 cm2 or any other valvular diseases for which surgery is indicated.~* Treatment with any loop diuretic (e.g., furosemide, bumetanide, torsemide, ethacrynic acid, etc.) in the 30 days prior to randomization.~* Ejection fraction of \<35% within the 3 months prior to randomization (most recent measure if more than one).~* AF/AFL as a result of surgery (postoperative AF/AFL) within 30 days prior to randomization.~* History of electrical cardioversion within the 7 calendar days prior to randomization.~* History of any polymorphic ventricular tachycardia including torsades de pointes.~* History or family history of long QT syndrome or other inherited arrhythmia syndrome.~* History of ventricular tachycardia requiring drug or device therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vanoxerine HCl (Type: EXPERIMENTAL): Vanoxerine HCl, 400 mg (2 x 200 mg capsules), orally, single dose
- Placebo (Type: PLACEBO_COMPARATOR): identically matching placebo capsules, orally, single-dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues